Company
JCR Pharmaceuticals Co. Ltd
Headquarters: Ashiya, Japan
Employees: 732
CEO: Mr. Shin Ashida
Market Cap
¥68.77 Billion
JPY as of Jan. 1, 2025
US$438.3 Million
JCR Pharmaceuticals Co. Ltd Categories
Japan Healthcare Drug Manufacturers—GeneralJapan Healthcare Japan Drug Manufacturers—General
Top Competitors by Market Capitalization
Industry: Drug Manufacturers—General
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
| Merck | $244.44 B |
| Roche | $219.35 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Detailed Description
JCR Pharmaceuticals Co., Ltd. engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, regenerative medicines, and drug substances in Japan. It offers various therapeutic product, which includes GROWJECT used for the treatment of growth hormone deficiency and short stature; IZCARGO to treat Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion used for the treatment of Fabry disease; and TEMCELL HS Inj used to treat acute graft-versus-host disease. The company also develops Epoetin Alfa BS and Darbepoetin Alfa BS Injections for the treatment of renal anemia. In addition, it sells medical devices and laboratory instruments. The company was incorporated in 1975 and is headquartered in Ashiya, Japan.
Stocks & Indices
JCR Pharmaceuticals Co. Ltd has the following listings and related stock indices.
Stock: JPX: 4552 wb_incandescent